Jane Street
BDTX icon

Jane Street’s Black Diamond Therapeutics BDTX Stock Holding History

Jane Street’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,400
Closed -$35K – 11574
2025
Q4 		$35K Buy
+14,400
New +$51K ﹤0.01% 10607
2024
Q4 		– Sell
-72,000
Closed -$313K – 9387
2024
Q3 		$313K Buy
+72,000
New +$392K ﹤0.01% 7957
2021
Q3 		– Sell
-26,400
Closed -$322K – 9921
2021
Q2 		$322K Buy
+26,400
New +$522K ﹤0.01% 8022

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jane Street's BDTX Position: Q2 2026 in Review

Jane Street increased its Black Diamond Therapeutics (BDTX) stake by 206% in Q2 2026, buying an estimated $477K and bringing the position to 289,712 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #7854.

Jane Street first reported a position in BDTX in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.34M in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Jane Street held 289,712 shares of Black Diamond Therapeutics worth $536K as of Q2 2026.
  • Jane Street bought 194,881 Black Diamond Therapeutics shares in Q2 2026, an estimated $477K.
  • Black Diamond Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7854 holding.
  • Jane Street first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Jane Street's Black Diamond Therapeutics position peaked at $2.34M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.